Skip to content

A study on the dermatological efficacy of oral administration of beauty capsule

A study on the dermatological efficacy of oral administration of beauty capsule - Evaluation of beauty ingredient for skin

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000025667
Enrollment
30
Registered
2017-01-18
Start date
2017-01-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Oral intake of active capsules twice a day for 8 weeks Oral intake of placebo capsules twice a day for 8 weeks

Sponsors

SOUKEN Co., Ltd
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Healthy female suffered from red skin

Exclusion criteria

Exclusion criteria: -Subjects who go to hospital regularly or went to hospital within the past 1 month for disease: skin, gastrointestinal system, liver, kidney, heart, blood pressure, and physical deconditioning. (Manual therapeutics, chiropractic and massage are not included.) -Subjects who are routinely taking oral medicine or applying external use medicine (ex. hypnotic, analgesic, anti-histamine, rhinitis drug, hormone preparation, cathartic, intestinal regulator, and others). -Subjects who have received medical cosmetic treatment before. -Subjects who have food or drug allergies. -Subjects who are pregnant, could be pregnant in near future, or are breast feeding. -Subjects who are participating in another clinical study. -Subjects who are deemed inappropriate to participate in this study by the principle investigator.

Design outcomes

Primary

MeasureTime frame
Evaluation of skin properties, e.g. skin color, transepidermal water loss, and skin hydration and blood parameters before and after capsule intake.

Countries

Japan

Contacts

Public ContactKo Masuda

SOUKEN Co., Ltd Management Division

k_masuda@mail.souken-r.com03-5408-1555

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026